Tags

Type your tag names separated by a space and hit enter

Insight in the Current Progress in the Largest Clinical Trials for Covid-19 Drug Management (As of January 2021).

Abstract

The outbreak of the COVID-19 pandemic has generated the largest global health crisis of the 21st century, evolving into accelerating socioeconomic disruption. In spite of all rapidly and widely emerging scientific data on epidemiology, diagnosis, prevention and treatment of the COVID-19 disease, severe acute respiratory coronavirus 2 (SARS-CoV-2) is continuing to propagate in lack of definitive and specific therapeutic agents. Current therapeutic strategies are mainly focused on viral inhibition by antiviral drugs and hampering the exuberant immune response of the host by immunomodulatory drugs. In this review, we have studied the reports of the largest clinical trials intended to COVID-19 treatment published during the first year of the pandemics. In general, these results concentrate on seven therapeutic options: remdesivir, chloroguine/hydroxychloroquine, lopinavir-ritonavir combination, corticosteroids, tocilizumab, convalescent plasma and monoclonal antibodies. In line with the reviewed data, as of January 2021, most of the evidence support the use of remdesivir in hospitalized patients with moderate and severe forms of the disease and provide reliable data on the substantial beneficial effect of corticosteroids in patients requiring supplemental oxygen. Moreover, preliminary RECOVERY trial results have demonstrated the efficacy of tociluzumab in the treatment of critically ill patients. The reports presenting the outcomes of the other immune-based therapies under investigation are enthusiastically awaited.

Authors+Show Affiliations

University Clinic of Hematology, Medical Faculty, University Ss. Cyril and Methodius, Skopje, Republic of North Macedonia.University Clinic of Hematology, Medical Faculty, University Ss. Cyril and Methodius, Skopje, Republic of North Macedonia.University Clinic of Infection Diseases and Febrile Conditions, Faculty of Medicine, University Ss. Cyril and Methodius, Skopje, Republic of North Macedonia.University Clinic of Infection Diseases and Febrile Conditions, Faculty of Medicine, University Ss. Cyril and Methodius, Skopje, Republic of North Macedonia.University Clinic of Infection Diseases and Febrile Conditions, Faculty of Medicine, University Ss. Cyril and Methodius, Skopje, Republic of North Macedonia.University Clinic of Hematology, Medical Faculty, University Ss. Cyril and Methodius, Skopje, Republic of North Macedonia.University Clinic of Hematology, Medical Faculty, University Ss. Cyril and Methodius, Skopje, Republic of North Macedonia.Faculty of Pharmacy, University Ss. Cyril and Methodius, Skopje, Republic of North Macedonia.University Clinic for Neurosurgery, Faculty of Medicine, University Ss. Cyril and Methodius, Skopje, Republic of North Macedonia.Faculty of Pharmacy, University Ss. Cyril and Methodius, Skopje, Republic of North Macedonia. Research Center for Genetic Engineering and Biotechnology "Georgi D. Efremov", Macedonian Academy of Sciences and Arts, Skopje, Republic of North Macedonia.Faculty of Pharmacy, University Ss. Cyril and Methodius, Skopje, Republic of North Macedonia.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

33894123

Citation

Panovska-Stavridis, Irina, et al. "Insight in the Current Progress in the Largest Clinical Trials for Covid-19 Drug Management (As of January 2021)." Prilozi (Makedonska Akademija Na Naukite I Umetnostite. Oddelenie Za Medicinski Nauki), vol. 42, no. 1, 2021, pp. 5-18.
Panovska-Stavridis I, Ridova N, Stojanoska T, et al. Insight in the Current Progress in the Largest Clinical Trials for Covid-19 Drug Management (As of January 2021). Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2021;42(1):5-18.
Panovska-Stavridis, I., Ridova, N., Stojanoska, T., Demiri, I., Stevanovic, M., Stojanovska, S., Ristevska, T., Dimkovski, A., Filipce, V., Dimovski, A., & Grozdanova, A. (2021). Insight in the Current Progress in the Largest Clinical Trials for Covid-19 Drug Management (As of January 2021). Prilozi (Makedonska Akademija Na Naukite I Umetnostite. Oddelenie Za Medicinski Nauki), 42(1), 5-18. https://doi.org/10.2478/prilozi-2021-0001
Panovska-Stavridis I, et al. Insight in the Current Progress in the Largest Clinical Trials for Covid-19 Drug Management (As of January 2021). Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2021 Apr 23;42(1):5-18. PubMed PMID: 33894123.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Insight in the Current Progress in the Largest Clinical Trials for Covid-19 Drug Management (As of January 2021). AU - Panovska-Stavridis,Irina, AU - Ridova,Nevenka, AU - Stojanoska,Tatjana, AU - Demiri,Ilir, AU - Stevanovic,Milena, AU - Stojanovska,Simona, AU - Ristevska,Tara, AU - Dimkovski,Aleksandar, AU - Filipce,Venko, AU - Dimovski,Aleksandar, AU - Grozdanova,Aleksandra, Y1 - 2021/04/23/ PY - 2021/4/24/entrez PY - 2021/4/25/pubmed PY - 2021/5/1/medline KW - COVID-19 KW - SARS-CoV-2 KW - antiviral drugs KW - immunomodulatory drugs KW - pandemic KW - remdesivir SP - 5 EP - 18 JF - Prilozi (Makedonska akademija na naukite i umetnostite. Oddelenie za medicinski nauki) JO - Pril (Makedon Akad Nauk Umet Odd Med Nauki) VL - 42 IS - 1 N2 - The outbreak of the COVID-19 pandemic has generated the largest global health crisis of the 21st century, evolving into accelerating socioeconomic disruption. In spite of all rapidly and widely emerging scientific data on epidemiology, diagnosis, prevention and treatment of the COVID-19 disease, severe acute respiratory coronavirus 2 (SARS-CoV-2) is continuing to propagate in lack of definitive and specific therapeutic agents. Current therapeutic strategies are mainly focused on viral inhibition by antiviral drugs and hampering the exuberant immune response of the host by immunomodulatory drugs. In this review, we have studied the reports of the largest clinical trials intended to COVID-19 treatment published during the first year of the pandemics. In general, these results concentrate on seven therapeutic options: remdesivir, chloroguine/hydroxychloroquine, lopinavir-ritonavir combination, corticosteroids, tocilizumab, convalescent plasma and monoclonal antibodies. In line with the reviewed data, as of January 2021, most of the evidence support the use of remdesivir in hospitalized patients with moderate and severe forms of the disease and provide reliable data on the substantial beneficial effect of corticosteroids in patients requiring supplemental oxygen. Moreover, preliminary RECOVERY trial results have demonstrated the efficacy of tociluzumab in the treatment of critically ill patients. The reports presenting the outcomes of the other immune-based therapies under investigation are enthusiastically awaited. SN - 1857-8985 UR - https://www.unboundmedicine.com/medline/citation/33894123/Insight_in_the_Current_Progress_in_the_Largest_Clinical_Trials_for_Covid_19_Drug_Management__As_of_January_2021__ L2 - https://content.sciendo.com/doi/10.2478/prilozi-2021-0001 DB - PRIME DP - Unbound Medicine ER -